Information and interesting ideas

Topics posted here will be in the realm of bioanalysis and biomarkers as part of new therapeutic development, with the occasional post of scientific topics that I find interesting.

Wednesday, June 7, 2023

Sciex Webinar: Driving more sensitive and selective bioanalysis using accurate mass spectrometry

 Sciex is having a webinar, Driving more sensitive and selective bioanalysis using accurate mass spectrometry  on Thursday, 29Jun23 at 10AM ET (getting in before Agilent's 3 hr webinar that I posted yesterday.

 From the Registration page (Register here).

Quantitation of small and large molecule therapeutics in biological matrices is important during drug development. Quadrupole-based liquid chromatography coupled with mass spectrometry (LC-MS) has been routinely adopted for the quantitation of therapeutics in bioanalytical laboratories. Advances in accurate mass spectrometry have enabled it to become a complementary option for quantitative bioanalysis. These advances include greater selectivity, improved mass resolution and the flexibility of time-of-flight (TOF) MS/MS for data analysis.

These advances include greater selectivity, improved mass resolution and the flexibility of time-of-flight (TOF) MS/MS for data analysis. Here, quantitative analysis was performed on the ZenoTOF 7600 system, where the application of the Zeno trap enhanced overall MS/MS sampling efficiency and boosted quantitative sensitivity for bioanalysis. 

What will you learn?

  • How to achieve low-level quantitation of small and large molecules in challenging biological matrices using the ZenoTOF 7600 system, featuring the Zeno trap for enhanced MS/MS sampling efficiency
  • How to streamline quantitation methods by collecting data over a wide MS/MS range for flexible post-acquisition data processing
  • How to increase productivity with a user-friendly interface and integrated platform for data acquisition, processing and management for routine bioanalysis using SCIEX OS software

No comments:

Post a Comment

FDA and CMS issue statement on LDTs: Americans Deserve Accurate and Reliable Diagnostic Tests, Wherever They Are Made

This joint statement notes the evolution of Laboratory Developed Tests (LDTs) from the initial rule and approach the FDA had for oversite, a...